Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhengzhou Univ. LSD1 compound 9e: sourced facts only. name: "The representative compound, 9e, proved to be a highly effective LSD1 inhibitor, with an IC50 value of 9.85 nM, and demonstrated exceptional selectivity for LSD1 over both MAOs and hERG." [PMID:40022881]; target: "The representative compound, 9e, proved to be a highly effective LSD1 inhibitor, with an IC50 value of 9.85 nM, and demonstrated exceptional selectivity for LSD1 over both MAOs and hERG." [PMID:40022881]; developer: "College of Chemistry, Zhengzhou University, Zhengzhou, Henan, 450001, PR China." [PMID:40022881]; stage: "compound 9e exhibited significant inhibitory activity against leukemia cells, especially MV-4-11, HL-60, and THP-1 cells, with IC50 values of 1.40, 1.54, and 1.96 μM respectively." [PMID:40022881]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhengzhou Univ. LSD1 compound 9e.